A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
This trial is a phase 3, double-blind, placebo-controlled, randomized withdrawal maintenance trial of brexpiprazole in subjects who require adjunctive treatment of MDD designed to fulfill a post-marketing commitment to the US Food and Drug Administration (FDA). There is a paucity of data on long-term use of the combination of ADT and an antipsychotic drug.The trial will assess long-term benefit of continuation of adjunctive therapy in subjects who achieve a level of clinical stabilization.
- Study Identifier: 831294
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required